Digital Health Platform for Type 2 Diabetes

(GUIDE Trial)

This trial tests an Integrated Digital Health (IDH) platform to help manage Type 2 diabetes. The researchers aim to determine if using the platform, with or without healthcare provider assistance, improves blood sugar control and other diabetes-related outcomes. The trial also explores how to integrate this platform into regular primary care. Participants should have had Type 2 diabetes for at least one year, a recent HbA1c blood sugar level between 8-11%, and own a smartphone. As an unphased trial, this study offers a unique opportunity to contribute to innovative diabetes care solutions.

Research has shown that the Integrated Digital Health (IDH) platform is generally safe for people with type 2 diabetes. Studies have found that digital health tools can improve blood sugar control and aid in weight loss. For instance, one study reported that users of digital health platforms lost 6.2% of their weight over six months, indicating that the platform is well-tolerated, with no major side effects reported.

Researchers are excited about the Integrated Digital Health (IDH) platform for type 2 diabetes because it offers a fresh approach to managing the condition. Unlike traditional treatments that often rely solely on medication and periodic glucose monitoring, the IDH platform integrates continuous digital monitoring with real-time data analysis. This setup can provide personalized feedback and support, potentially improving patient engagement and self-management. Additionally, the IDH platform with provider engagement takes it a step further by facilitating direct communication between patients and healthcare providers, allowing for timely adjustments in treatment plans. These features could lead to more precise and responsive diabetes management compared to the current standard of care.

Research has shown that digital health tools can effectively manage Type 2 diabetes. In this trial, participants will divide into different groups to evaluate these tools' effectiveness. Group A will use Continuous Glucose Monitoring (CGM) only. Group B will use the Integrated Digital Health (IDH) platform without provider engagement, while Group C will use the IDH platform with provider engagement. Studies have found that digital tools can lead to better blood sugar control without increasing the risk of severe low blood sugar. Specifically, one study found that patients using digital tools experienced significant improvements in blood sugar levels and overall health. Another study showed that involving healthcare providers in these digital platforms can further enhance diabetes management. This evidence suggests that digital health tools, combined with support from healthcare providers, can improve diabetes outcomes.⁶⁷⁸⁹¹⁰